The 53-kb biosynthetic gene cluster for the novel anticholesterol natural product herboxidiene was identified in Streptomyces chromofuscus ATCC 49982 by genome sequencing and gene inactivation. In addition to herboxidiene, a biosynthetic intermediate, 18-deoxy-herboxidiene, was also isolated from the fermentation broth of S. chromofuscus ATCC 49982 as a minor metabolite.
H eart disease is a major threat to human health and remains the world's top killer. Hypercholesterolemia is a primary risk factor for coronary heart disease. Lovastatin and other statins are widely used in clinics to lower cholesterol levels. However, some side effects of statins have been reported, such as muscle and liver problems (19) . Thus, new anticholesterol agents are needed. Herboxidiene (compound 1, Fig. 1A ) was isolated from Streptomyces chromofuscus A7847 (ATCC 49982) as a novel polyketide which selectively and effectively controls several annual weed species (10, 16) . Later, compound 1 was found to effectively reduce plasma cholesterol and possess stronger low-density lipoprotein receptor upregulation activity than tricholstatin A and TMC-49A, representing a new type of anticholesterol molecule (13) . Additionally, it also has strong cytotoxic activities and induces both G 1 and G 2 /M arrest in human tumor cell line WI-38 (50% inhibitory concentrations range from 3.7 nM to 0.99 M) (9, 23) . Because of its promising biological activities, several chemical synthetic approaches toward compound 1 have recently been attempted (5, 7, 8, 26) . One of the most recent chemical syntheses of compound 1 was accomplished from two lactate-derived chiral ketones in 14 steps with an 8% overall yield (21) . However, these multistep chemical processes are not efficient and flexible enough for the synthesis of new herboxidiene analogs. Biosynthesis thus represents an attractive approach to generate structural diversity for more-active and less-toxic molecules.
For the bacterial strains and plasmids used in this study, see Table S1 in the supplemental material. To locate the herboxidiene biosynthetic gene cluster and better understand this pharmaceutically important strain, the genomic DNA of S. chromofuscus ATCC 49982 was extracted and sequenced using a 454 next-generation sequencing system, yielding approximately 9.6 Mb of sequence data (GC content of 71.25%). Analysis of the sequenced genome was performed with RAST (rapid annotation using subsystem technology) (2), which revealed 8,264 open reading frames (ORFs) encoding genes averaging 1,162 bp. Among the 8,264 putative proteins, 3,531 showed similarity to proteins with functional assignments. Only two contigs were found to contain a complete type I PKS gene cluster. Contig 013 (133,019 bp) contains a gene cluster that encodes a type I PKS consisting of a loading module and 11 extension modules. This PKS is proposed to synthesize a dodecaketide and thus is unlikely to be the herboxidiene synthase. Contig 008 (159,472 bp, GenBank accession number JN671974) was found to contain a gene cluster covering a 53-kb region (herA to -G, Fig. 1B ) that encodes a nonaketide synthase and three tailoring enzymes, including an epoxidase, a methyltransferase, and a cytochrome P450 hydroxylase. The organization of the gene cluster is consistent with the structural characteristics of compound 1, thus representing a possible gene cluster involved in herboxidiene biosynthesis. The ORFs in the gene cluster and flanking regions are listed in Table 1 .
Among the seven herboxidiene biosynthetic genes, herB, -C, and -D encode a multimodular type I PKS comprising a loading module and eight extension modules. The organization of the PKS and proposed herboxidiene biosynthetic pathway are shown in Fig. 1A . Ketosynthase (KS), acyltransferase (AT), and acyl carrier protein (ACP) domains are essential for chain elongation and exist in all of the extension modules. Ketoreductase (KR), dehydratase (DH), and enoyl reductase (ER) domains were found occasionally between AT and ACP for reductive modifications of the ␤-keto group formed from each extension step. The loading module in HerB contains a KS Q domain whose active-site Cys is replaced by a Glu, while the KS domains in the eight extension modules harbor the typical active-site sequence DTACS (17) . KS Q lacks condensation activity but retains the ability to decarboxylate dicarboxylic acid starters (4, 17) . In this herboxidiene biosynthetic pathway, the KS Q domain is proposed to decarboxylate methylmalonyl-ACP to yield propionyl-ACP, which is subsequently used as the starter unit to initiate elongation. AT domains are responsible for selecting and transferring the starter and extender units for polyketide chain synthesis. In keeping with the structure of the resulting molecule, the ATs in modules 1, 2, 3, 5, and 6, as well as AT0 in the loading module, are presumed to be specific for methylmalonyl coenzyme A (CoA), while the other ATs are proposed to take malonyl-CoA (8, 25) . Further alignment analysis revealed that all of the AT domains contain the conserved motifs which correlate with the malonyl-CoA and methylmalonyl-CoA specificity, as shown in Fig. 2A (11, 22) . All nine ACP domains exhibit the GxDS motif in which the conserved Ser residue is required for posttranslational attachment of the 4=-phosphopantetheinyl cofactor (6, 20) . Sequence analysis (Fig. 2B) showed that KR3, -4, -5, -6, -7, and -8 all contain the same conserved motifs to produce an "R" ␤-hydroxyl group, thus belonging to type B1. KR1 is predicted to be a type A1 KR that forms an "S" hydroxyl group (11) . However, the conserved motifs of KR2 are obscure and its type remains unclear. Six DH and two ER domains were found in the herboxidiene PKS. Alignment of the DH domains revealed the conserved HxxxGxxxxP motif, which contains the proposed active-site His (1, 6). Both ER3 and ER7 contain the highly conserved sequence LxHxxxGGVG, which is the proposed NADPH-binding site (6) . All of these catalytic domains work together to yield a linear 19-carbon nonaketide, which is released from the PKS by a C-terminal thioesterase (TE) domain that contains the conserved GxSxG and PGDH motifs (27) . A tetrahydropyran ring is subsequently formed between C-3 and C-7, likely through a spontaneous process, as shown in Fig. 1A .
Three genes (herE, herF, and herG) encoding post-PKS tailoring enzymes were found downstream of the PKS genes. HerE shows 58% identity to the epoxidase PldD for pladienolide biosynthesis (15) and is considered responsible for the epoxidation of the C-14 -C-15 double bond. HerF is a putative O-methyltransferase, which likely methylates the 17-OH. HerG shows 50% identity with a cytochrome P450 monooxygenase in the biotransformation of terfenadine (14) and is predicted to catalyze the C-18 hydroxylation.
A putative regulatory gene, herA, is located upstream of the six biosynthetic genes, which is proposed to be involved in herboxidiene biosynthesis as a pathway-specific regulator. HerA belongs to the LacI transcriptional regulator family and contains a ligand binding domain (18, 24) . No transporter genes are present in the gene cluster and flanking regions. Since compound 1 was found to be a major extracellular metabolite in the fermentation broth of S. chromofuscus ATCC 49982, the excretion of this compound may occur through diffusion or actions of certain general transporters in the cells.
To confirm that the discovered gene cluster is really involved in herboxidiene biosynthesis, AT4 in HerC was disrupted by means of single-crossover homologous recombination (3, 12) . Briefly, a 1.18-kb HindIII/EcoRI fragment (see Fig. S1 in the supplemental material) was amplified from the genomic DNA with primers A and B (5=-AAAGAATTCCTGAAGTCGAACATCGGGCACA-3= and 5=-AAAAAGCTTCATCAGCGGGGAGTGGAAGG-3=) and inserted into the HindIII/EcoRI site of pKC1139 to yield pLS-6 for insertional inactivation of herC. The plasmid was introduced into S. chromofuscus by intergeneric conjugation from Escherichia coli ET12567 (3, 12) . The apramycin-resistant colonies appearing at 37°C were identified as the integrating mutants, in which a singlecrossover homologous recombination event took place (see Fig.  S2A in the supplemental material). The genotypes of the resulting strains were further confirmed by PCR amplification with both genome-and vector-specific primers including Pcheck1 (5=-GCG TGACGGACCCAGTAGGC-3=), Pcheck2 (5=-GAGCGGATAAC AATTTCACACAGG-3=) (RV-M), Pcheck3 (5=-GTACGGGCAG AACCGGGACC-3=), Pcheck4 (5=-CGCCAGGGTTTTCCCAGT CACGAC-3=) (M13-47), Pcheck5 (5=-GCGACGTACGGGCAGA ACC-3=), and Pcheck6 (5=-CGTGACGGACCCAGTAGGC-3=). The 1.35-and 1.26 -kb fragments were, respectively, amplified from the mutant mHER1001 using Pcheck1/Pcheck2 and Pcheck3/Pcheck4 (see Fig. S2B in the supplemental material), indicating that pLS-6 was inserted into the genome. A PCR that spanned the disrupted region was also conducted using Pcheck5/ Pcheck6. In contrast to the wild type, the 1.37-kb gene fragment in herC could not be amplified from the genomic DNA of mHER1001 (see Fig. S2C in the supplemental material), which eliminated the possibility of the additional herC copy in the mutant. All of the PCR products were ligated into pJET1.2 and confirmed by sequencing. Thus, we confirmed the disruption of AT4 in HerC in mHER1001.
In order to isolate the standard of compound 1 for analysis of its production by the mutant, the wild-type strain was fermented in 4 liters of YM medium (0.4% glucose, 0.4% yeast extract, 1% malt extract, pH 7.3) at 28°C and 240 rpm for 8 days. The fermentation broth was extracted three times with 3.5 liters of ethyl acetate. Fractionation of the concentrated extract on a Diaion HP-20 column and further purification by high-performance liquid chromatography (HPLC) yielded 17 mg of compound 1 and 1.3 mg of a minor metabolite, compound 2. For the spectral data obtained for compounds 1 and 2, see the supplemental material. Electrospray ionization-mass spectrometry of compound 2 showed a quasimolecular ion
Ϫ at m/z 421, indicating that the molecular mass of this compound is 422 Da, which is 16 Da less than the molecular mass of compound 1. This suggested that compound 2 could be the 18-deoxy precursor of compound 1. The 1 H nuclear magnetic resonance spectrum of compound 2 was very similar to that of compound 1 (see the supplemental material), except that the signals at ␦ 3.77 (dq, 6.5, 6.2 Hz, H-18) and 1.10 (d, 6.5 Hz, H 3 -19) in compound 1 were replaced by those assignable to a methylene group at ␦ 1.55 and 1.62 and a methyl group at ␦ 0.86 (t, 7.6 Hz) in compound 2, respectively. The 1 H-1 H correlation spectroscopy spectrum of compound 2 showed that the methylene group (␦ 1.55 and 1.62) correlated with the methyl group (␦ 0.86) and H-17 (␦ 3.10). Therefore, the structure of compound 2 was determined as 18-deoxy-herboxidiene (Fig. 1A) , which is likely to be an intermediate in herboxidiene biosynthesis.
To examine the effect of the disruption of herC on herboxidiene biosynthesis, both S. chromofuscus ATCC 49982 and mHER1001 were grown in 100 ml of YM medium and extracted as described above. The extracts were analyzed using an Agilent ZORBAX SB-C 18 column (5 m, 4.6 by 250 mm) on an Agilent 1200 HPLC apparatus, eluted with 75% methanolwater (containing 0.1% trifluoroacetic acid) at 1 ml/min for 60 min. HPLC trace ii in Fig. 3 clearly shows that the production of both compounds 1 and 2 was abolished in mHER1001, indicating that herC is essential for herboxidiene biosynthesis. Successful inactivation of this gene cluster not only revealed its involvement in herboxidiene biosynthesis but also confirmed the genetic manipulability of the herboxidiene-producing strain, which makes it feasible to further conduct genetic and metabolic engineering of herboxidiene biosynthesis for novel analogs.
